U.S. Pharmacopeia (USP) Convention, an official public standards-setting authority for all prescription and over-the-counter medicines sold in the United States, on December 4, 2008 transferred all rights, ownership and management of the overall MEDMARX reporting program to Quantros.
This announcement comes one year after Quantros and USP formalized a strategic partnership wherein Quantros assumed all operations, support, marketing and sales for the MEDMARX program. During the past year Quantros has accelerated enhancements to the MEDMARX platform including seamless integration with the Quantros Safety and Risk Management (SRM) solution for patient safety to provide greater visibility and analysis capabilities related to Medication Errors and Adverse Drug Reactions (ADRs). Quantros and USP have worked collaboratively over the past year to create a more robust database of medication errors and provide broader access to the MEDMARX program. These efforts have led to an expanded comparative medication error events data repository for the advancement of medication safety improvement efforts within healthcare. According to USP, "Quantros is well positioned to take over the complete MEDMARX operation, from data collection to analysis to dissemination."
Under the terms of this transition, Quantros will take full ownership of the MEDMARX program and all associated intellectual property. Quantros will continue to further and manage all aspects of the MEDMARX program including operations, support, application enhancement and sales and marketing as it has done for the past year. In addition, Quantros will work with the MEDMARX program to support public health knowledge concerning medication errors and ADRs. The MEDMARX program will continue to be offered as a standalone application or as an integrated offering with Quantros SRM. Quantros will continue to collaborate with USP to assist in their ongoing data standards initiatives based on the knowledge created from the MEDMARX program.